Literature DB >> 36102964

Additive value of [18F]PI-2620 perfusion imaging in progressive supranuclear palsy and corticobasal syndrome.

Sabrina Katzdobler1,2,3, Alexander Nitschmann4, Johannes Levin1,2,3, Matthias Brendel5,6,7, Henryk Barthel8, Gerard Bischof9,10, Leonie Beyer4, Ken Marek11,12, Mengmeng Song4, Olivia Wagemann1,2, Carla Palleis1,2,3, Endy Weidinger1,2, Anne Nack1, Urban Fietzek1, Carolin Kurz13, Jan Häckert13,14, Theresa Stapf13, Christian Ferschmann4, Maximilian Scheifele4, Florian Eckenweber4, Gloria Biechele4, Nicolai Franzmeier15, Anna Dewenter15, Sonja Schönecker1, Dorothee Saur16, Matthias L Schroeter17,18,19, Jost-Julian Rumpf16, Michael Rullmann8, Andreas Schildan8, Marianne Patt8, Andrew W Stephens20, Thilo van Eimeren9, Bernd Neumaier9,21, Alexander Drzezga9,10,22, Adrian Danek1,2, Joseph Classen16, Katharina Bürger15, Daniel Janowitz15, Boris-Stephan Rauchmann14,23, Sophia Stöcklein23, Robert Perneczky2,3,14,24, Florian Schöberl1, Andreas Zwergal1, Günter U Höglinger2,3,25, Peter Bartenstein3,4, Victor Villemagne26,27,28, John Seibyl11,12, Osama Sabri8.   

Abstract

PURPOSE: Early after [18F]PI-2620 PET tracer administration, perfusion imaging has potential for regional assessment of neuronal injury in neurodegenerative diseases. This is while standard late-phase [18F]PI-2620 tau-PET is able to discriminate the 4-repeat tauopathies progressive supranuclear palsy and corticobasal syndrome (4RTs) from disease controls and healthy controls. Here, we investigated whether early-phase [18F]PI-2620 PET has an additive value for biomarker based evaluation of 4RTs.
METHODS: Seventy-eight patients with 4RTs (71 ± 7 years, 39 female), 79 patients with other neurodegenerative diseases (67 ± 12 years, 35 female) and twelve age-matched controls (69 ± 8 years, 8 female) underwent dynamic (0-60 min) [18F]PI-2620 PET imaging. Regional perfusion (0.5-2.5 min p.i.) and tau load (20-40 min p.i.) were measured in 246 predefined brain regions [standardized-uptake-value ratios (SUVr), cerebellar reference]. Regional SUVr were compared between 4RTs and controls by an ANOVA including false-discovery-rate (FDR, p < 0.01) correction. Hypoperfusion in resulting 4RT target regions was evaluated at the patient level in all patients (mean value - 2SD threshold). Additionally, perfusion and tau pattern expression levels were explored regarding their potential discriminatory value of 4RTs against other neurodegenerative disorders, including validation in an independent external dataset (n = 37), and correlated with clinical severity in 4RTs (PSP rating scale, MoCA, activities of daily living).
RESULTS: Patients with 4RTs had significant hypoperfusion in 21/246 brain regions, most dominant in thalamus, caudate nucleus, and anterior cingulate cortex, fitting to the topology of the 4RT disease spectrum. However, single region hypoperfusion was not specific regarding the discrimination of patients with 4RTs against patients with other neurodegenerative diseases. In contrast, perfusion pattern expression showed promise for discrimination of patients with 4RTs from other neurodegenerative diseases (AUC: 0.850). Discrimination by the combined perfusion-tau pattern expression (AUC: 0.903) exceeded that of the sole tau pattern expression (AUC: 0.864) and the discriminatory power of the combined perfusion-tau pattern expression was replicated in the external dataset (AUC: 0.917). Perfusion but not tau pattern expression was associated with PSP rating scale (R = 0.402; p = 0.0012) and activities of daily living (R =  - 0.431; p = 0.0005).
CONCLUSION: [18F]PI-2620 perfusion imaging mirrors known topology of regional hypoperfusion in 4RTs. Single region hypoperfusion is not specific for 4RTs, but perfusion pattern expression may provide an additive value for the discrimination of 4RTs from other neurodegenerative diseases and correlates closer with clinical severity than tau pattern expression.
© 2022. The Author(s).

Entities:  

Keywords:  Neuronal injury; PET; Perfusion; Tau; [18F]PI-2620

Year:  2022        PMID: 36102964     DOI: 10.1007/s00259-022-05964-w

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   10.057


  32 in total

Review 1.  Four-repeat tauopathies.

Authors:  Thomas W Rösler; Amir Tayaranian Marvian; Matthias Brendel; Niko-Petteri Nykänen; Matthias Höllerhage; Sigrid C Schwarz; Franziska Hopfner; Thomas Koeglsperger; Gesine Respondek; Kerstin Schweyer; Johannes Levin; Victor L Villemagne; Henryk Barthel; Osama Sabri; Ulrich Müller; Wassilios G Meissner; Gabor G Kovacs; Günter U Höglinger
Journal:  Prog Neurobiol       Date:  2019-06-22       Impact factor: 11.685

2.  18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.

Authors:  Mohsen Khosravi; Jonah Peter; Nancy A Wintering; Mijail Serruya; Sara Pourhassan Shamchi; Thomas J Werner; Abass Alavi; Andrew B Newberg
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

3.  Cortical [18 F]PI-2620 Binding Differentiates Corticobasal Syndrome Subtypes.

Authors:  Carla Palleis; Matthias Brendel; Johannes Levin; Günter U Höglinger; Anika Finze; Endy Weidinger; Kai Bötzel; Adrian Danek; Leonie Beyer; Alexander Nitschmann; Maike Kern; Gloria Biechele; Boris-Stephan Rauchmann; Jan Häckert; Matthias Höllerhage; Andrew W Stephens; Alexander Drzezga; Thilo van Eimeren; Victor L Villemagne; Andreas Schildan; Henryk Barthel; Marianne Patt; Osama Sabri; Peter Bartenstein; Robert Perneczky; Christian Haass
Journal:  Mov Disord       Date:  2021-05-05       Impact factor: 10.338

4.  FDG-PET patterns associated with underlying pathology in corticobasal syndrome.

Authors:  Matteo Pardini; Edward D Huey; Salvatore Spina; William C Kreisl; Silvia Morbelli; Eric M Wassermann; Flavio Nobili; Bernardino Ghetti; Jordan Grafman
Journal:  Neurology       Date:  2019-01-30       Impact factor: 9.910

Review 5.  Tau and tauopathies.

Authors:  Thomas Arendt; Jens T Stieler; Max Holzer
Journal:  Brain Res Bull       Date:  2016-09-09       Impact factor: 4.077

6.  Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria.

Authors:  Günter U Höglinger; Gesine Respondek; Maria Stamelou; Carolin Kurz; Keith A Josephs; Anthony E Lang; Brit Mollenhauer; Ulrich Müller; Christer Nilsson; Jennifer L Whitwell; Thomas Arzberger; Elisabet Englund; Ellen Gelpi; Armin Giese; David J Irwin; Wassilios G Meissner; Alexander Pantelyat; Alex Rajput; John C van Swieten; Claire Troakes; Angelo Antonini; Kailash P Bhatia; Yvette Bordelon; Yaroslau Compta; Jean-Christophe Corvol; Carlo Colosimo; Dennis W Dickson; Richard Dodel; Leslie Ferguson; Murray Grossman; Jan Kassubek; Florian Krismer; Johannes Levin; Stefan Lorenzl; Huw R Morris; Peter Nestor; Wolfgang H Oertel; Werner Poewe; Gil Rabinovici; James B Rowe; Gerard D Schellenberg; Klaus Seppi; Thilo van Eimeren; Gregor K Wenning; Adam L Boxer; Lawrence I Golbe; Irene Litvan
Journal:  Mov Disord       Date:  2017-05-03       Impact factor: 10.338

7.  Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy.

Authors:  Matthias Brendel; Henryk Barthel; Thilo van Eimeren; Ken Marek; Leonie Beyer; Mengmeng Song; Carla Palleis; Mona Gehmeyr; Urban Fietzek; Gesine Respondek; Julia Sauerbeck; Alexander Nitschmann; Christian Zach; Jochen Hammes; Michael T Barbe; Oezguer Onur; Frank Jessen; Dorothee Saur; Matthias L Schroeter; Jost-Julian Rumpf; Michael Rullmann; Andreas Schildan; Marianne Patt; Bernd Neumaier; Olivier Barret; Jennifer Madonia; David S Russell; Andrew Stephens; Sigrun Roeber; Jochen Herms; Kai Bötzel; Joseph Classen; Peter Bartenstein; Victor Villemagne; Johannes Levin; Günter U Höglinger; Alexander Drzezga; John Seibyl; Osama Sabri
Journal:  JAMA Neurol       Date:  2020-11-01       Impact factor: 18.302

8.  Early-phase [18F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury.

Authors:  Leonie Beyer; Alexander Nitschmann; Henryk Barthel; Thilo van Eimeren; Marcus Unterrainer; Julia Sauerbeck; Ken Marek; Mengmeng Song; Carla Palleis; Gesine Respondek; Jochen Hammes; Michael T Barbe; Özgür Onur; Frank Jessen; Dorothee Saur; Matthias L Schroeter; Jost-Julian Rumpf; Michael Rullmann; Andreas Schildan; Marianne Patt; Bernd Neumaier; Olivier Barret; Jennifer Madonia; David S Russell; Andrew W Stephens; Sigrun Roeber; Jochen Herms; Kai Bötzel; Johannes Levin; Joseph Classen; Günter U Höglinger; Peter Bartenstein; Victor Villemagne; Alexander Drzezga; John Seibyl; Osama Sabri; Matthias Brendel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-04-21       Impact factor: 9.236

9.  Dual-Phase β-Amyloid PET Captures Neuronal Injury and Amyloidosis in Corticobasal Syndrome.

Authors:  Julia Schmitt; Carla Palleis; Julia Sauerbeck; Marcus Unterrainer; Stefanie Harris; Catharina Prix; Endy Weidinger; Sabrina Katzdobler; Olivia Wagemann; Adrian Danek; Leonie Beyer; Boris-Stephan Rauchmann; Axel Rominger; Mikael Simons; Peter Bartenstein; Robert Perneczky; Christian Haass; Johannes Levin; Günter U Höglinger; Matthias Brendel
Journal:  Front Aging Neurosci       Date:  2021-05-13       Impact factor: 5.750

Review 10.  A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers.

Authors:  Clifford R Jack; David A Bennett; Kaj Blennow; Maria C Carrillo; Howard H Feldman; Giovanni B Frisoni; Harald Hampel; William J Jagust; Keith A Johnson; David S Knopman; Ronald C Petersen; Philip Scheltens; Reisa A Sperling; Bruno Dubois
Journal:  Neurology       Date:  2016-07-01       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.